Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | SCN1A | P35498 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.58 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10597961 | 0.85 | ATM (0.50) | ATML3MBTL1CHRM3ALDH1A1HRH1 | |
| SCHEMBL14198330 | 0.82 | CYP19A1 (0.55) | ATML3MBTL1CHRM3ALDH1A1HRH1 | |
| SCHEMBL8812539 | 0.82 | HRH1 (0.73) | ATML3MBTL1CHRM3ALDH1A1HRH1 | |
| SCHEMBL894817 | 0.82 | HRH1 (0.73) | ATML3MBTL1CHRM3ALDH1A1HRH1 | |
| SCHEMBL8812545 | 0.82 | HRH1 (0.73) | ATML3MBTL1CHRM3ALDH1A1HRH1 | |
| SCHEMBL55533 | 0.82 | HRH1 (0.67) | HRH1KCNH2 | |
| SCHEMBL25453182 | 0.81 | CHRM3 (0.55) | ATML3MBTL1CHRM3ALDH1A1HRH1 | |
| SCHEMBL14020878 | 0.81 | HRH1 (0.65) | ALDH1A1HRH1KCNH2 | |
| SCHEMBL8931668 | 0.80 | CHRM3 (0.46) | ATML3MBTL1CHRM3ALDH1A1HRH1 | |
| SCHEMBL7434429 | 0.80 | ALDH1A1 (0.70) | ALDH1A1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| EP-1887008-B1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| EP-3297992-B1 | HETEROCYCLICALKYL DERIVATIVE COMPOUNDS AS SELECTIVE HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2020-02-05 | — | — | EP | disclosed |
| US-9493420-B2 | Quinoline derivatives and uses thereof | PORTLAND STATE UNIVERSITY (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493420-B2 | Quinoline derivatives and uses thereof | PORTLAND STATE UNIVERSITY (US) | 2016-11-15 | — | — | US | disclosed |
| US-20130310348-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | STATE UNIVERSITY (US) | 2013-11-21 | — | — | US | disclosed |
| US-8524739-B2 | Quinoline derivatives and uses thereof | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524739-B2 | Quinoline derivatives and uses thereof | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2013-09-03 | — | — | US | disclosed |
| US-8153385-B2 | Target protein and target gene in drug designing and screening method | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153385-B2 | Target protein and target gene in drug designing and screening method | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| WO-2005103041-A9 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005103041-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HYPNION, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2003032912-A9 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-1443929-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | Hypnion, Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040142972-A1 | CNS target modulators | HYPNION, INC. | 2004-07-22 | — | — | US | disclosed |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003032912-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| US-5077301-A | 4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDYLPHENYLALKANE DERIVATIVES AS ANTIHISTAMINES AND METHODS OF TREATMENT OF AN ALLERGIC RESPONSE | SCHAPER & BRUEMMER GMBH & CO. KG (DE) | 1991-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HCRTR2, CNR2, CNR1 | ATM 4210/4885L3MBTL1 3982/4885CHRM3 22/4885 |
| US-20130310348-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | RECQL, QARS1, QTRT1 | ATM 3151/4885L3MBTL1 3204/4885CHRM3 974/4885 |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, CNR2, CNR1 | ATM 4210/4885L3MBTL1 3982/4885CHRM3 22/4885 |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, HRH3, HCRTR1 | ATM 3868/4885L3MBTL1 3892/4885CHRM3 58/4885 |
| US-20040142972-A1 | CNS target modulators | HCRTR2, CNR2, CNR1 | ATM 4426/4885L3MBTL1 3955/4885CHRM3 19/4885 |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | ATM 3657/4885L3MBTL1 1539/4885CHRM3 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.